Expert review of pharmacoeconomics & outcomes research
Cost-effectiveness of second- or third-line treatment with tisotumab vedotin for metastatic or recurrent cervical cancer.
María Del Pilar Briceño-Casado, Adrián Sánchez Vegas, Emilio Jesús Alegre-Del-Rey, Antonio Olry de Labry Lima
Published: 202510.1080/14737167.2025.2603941
Abstract
OBJECTIVE: To evaluate the cost-effectiveness of tisotumab vedotin (TV) versus single-agent chemotherapy in recurrent or metastatic cervical cancer (r/mCC) after failure of first-line treatment, from the perspective of the Spanish National Health Sys…
Preview only. Read the full abstract at the source